# Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

> **NCT03569007** · PHASE3 · TERMINATED · sponsor: **9 Meters Biopharma, Inc.** · enrollment: 307 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Larazotide
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT03569007
- **Lead sponsor:** 9 Meters Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-29
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-07-21
- **Target enrollment:** 307 (ACTUAL)
- **Why stopped:** Trial terminated by Sponsor
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569007, "Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03569007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*